Efficacy and Tolerability of a Double-Conjugated Retinoid/Alpha Hydroxy Acid Cream and a **Complementary Skincare Regimen in a Series of Subjects of Varying Skin Types** with Mild to Moderate Blemish-Prone Skin

INTRODUCTION

- Blemishes are one of the most common skin conditions treated by dermatologists.^{1,2}
- Retinoids, alpha hydroxy acids (AHAs) and beta hydroxy acids (BHAs; salicylic acid) are often used first-line and in combination with other products to improve skin clarity.^{1,3,4}
- A balance must exist in reducing sebum and improving skin clarity, while minimizing irritation and disruption of the skin barrier. Further, darker skin tones are prone to Post-inflammatory Hyperpigmentation (PIH).^{2,3}
- A formulation leveraging double-conjugated retinoid technology with additional lactic acid, salicylic acid and other key ingredients to support the skin barrier (AHARet-SA) demonstrated early improvements in the appearance of skin clarity and pores in a study population that included subjects with predominantly lighter skin tones.⁵
- Herein, we describe the evaluation of AHARet-SA Serum and a complementary skincare regimen that included exfoliating peel pads comprised of a doubleconjugated retinoid/AHA and a triple-acid blend (glycolic, lactic and salicylic acids), a cleansing gel, moisturizer and sunscreen in a series of subjects with varying skin types and mild to moderate blemish-prone skin.

OBJECTIVES

Evaluate the efficacy, tolerability and subject satisfaction of AHARet-SA and a complementary skincare regimen in a series of subjects with varying skin types and mild to moderate blemish-prone skin.

METHODS

- This single-center, open-label clinical trial evaluated the efficacy, tolerability and subject satisfaction of a skincare regimen in subjects 30-55 years of age with mild to moderate blemish-prone skin according to the Investigator Global Assessment 5point scale (0 [Clear skin; no inflammatory or noninflammatory lesions] to 4 [Severe; up to many noninflammatory and inflammatory lesions/no more than a few nodular lesions]).
- This 12-week regimen included:
 - AM: Cleansing Gel and a Mineral-based Sunscreen Stick (SPF 56)
 - PM: Cleansing Gel, Exfoliating Peel Pads 3x/week (M-W-F) for the first 8 weeks; 2x/week (M & F); AHARet-SA Serum
 - AM/PM (Optional): Lightweight Moisturizer
- Exclusion criteria included dermatological disorders (e.g., severe acne vulgaris), autoimmune diseases, acute illness, open wound/lesion or irritated skin in the area to be treated; and, subjects who were pregnant, lactating or planning a pregnancy during the study period.
- Subjects were deemed eligible for inclusion in the study following a 2-week wash out period of any cosmetic product containing AHAs, BHAs, peptides, growth factors, skin lightening/brightening agents, non-prescription vitamin A derivatives, plant stem cell extracts, vitamin C-based topical antioxidants, other antioxidants or like products; and following a 4-week wash out period of products containing prescription retinoids or hydroquinone.
- Subjects who had taken Isotretinoin within the prior 6 months or had undergone chemical peels, microdermabrasion, microneedling, or a like procedure within the prior 3 months, were also excluded from study participation.
- Improvements from baseline in Skin Clarity were based on the use of the 5-point Investigator Global Assessment Scale (0 [Clear] to 4 [Severe]) at 4, 8, and 12 weeks. Changes in the appearance of Skin Tone, Pore Size, Fine lines and Wrinkles,
- Erythema, and Dryness/Flaking were assessed from baseline at 4, 8, and 12 weeks using a 6-point categorical scale (0 [None] to 5 [Severe]).
- Digital images were obtained at baseline, 4, 8, and 12-weeks using Canfield VISIA Imaging Systems (Canfield Scientific Inc., Parsippany, NJ).
- Subjects completed self-assessment questionnaires through week 12.
- Adverse Events (AEs) were captured throughout the study period.



Hartman CL, MD, FAAD¹; Dyck RM, MD¹; Nelson DB, RN, MPH²

¹Skin Wellness Dermatology, Birmingham, AL; ²skinbetter science, LLC, Phoenix, AZ

RESULTS


DEMOGRAPHICS

- Eleven (11) subjects were enrolled, and 8 subjects completed the study.
- All subjects were female with a mean age of 38 years. • Fifty-five percent (55%) of subjects were FST IV, 27% were FST V, and 1 subject each
- was FST I and FST III.
- 82% of enrolled subjects were African American.

EFFICACY

- As early as week 4, significant mean percent improvement from baseline in Skin Clarity occurred (14%; p=.04) with continued, progressive improvement through week 12 (52%; *p*=.004) (Table 1).
- There were significant improvements in the appearance of Skin Tone (15%; p=.01) and Pore Size (22%; p=.01) by week 8 with continued improvements through week 12 (34%, p=.003; 23%, p=.01, respectively; Figures 1-3).
- Visible improvements in the appearance of PIH were observed. For Dryness/Flaking, the mean score at baseline was 0 (none), and only minor
- increases were observed over time. Mean improvement in Erythema and Fine Lines and Wrinkles was minimal throughout the study; however, this may be due to low mean scores at baseline in both categories, and a younger subject demographic.
- By week 12, 75% of subjects demonstrated a >1-grade improvement in Skin Clarity, with 63% demonstrating \geq 2-grade improvement from baseline.

Table 1. Mean Percent Improvement from Baseline.



SUBJECT SATISFACTION

- Subjects reported high levels of satisfaction throughout the study period. • After only 4 weeks, 80% of subjects reported their skin felt less oily or greasy, and
- healthier looking with less visible pores. • After 12 weeks, 88% of subjects reported the overall appearance and texture of their skin improved, noting their skin appeared less blotchy, more even looking, with fewer blemishes or breakouts, and less shiny.
- All subjects reported they would continue to use the products at the conclusion of the study.

TOLERABILITY

- All AEs were mild and transient, and possibly related to study products. AEs included mild dryness, stinging/burning (with initial application), breakouts,
- and itching. No subject discontinued the study owing to an AE.

This study was sponsored by skinbetter science, LLC.

Dr. Hartman and Dr. Dyck served as study investigators. Ms. Nelson is an employee of skinbetter science.




Figure 2: Improvement from baseline to week 8.





Figure 3: Improvement from baseline to week 12.



CONCLUSIONS

A skincare regimen comprised of products formulated with a doubleconjugated retinoid/AHA, lactic, glycolic and salicylic acids and additional ingredients to support the skin barrier demonstrated visible improvements in Skin Clarity in subjects with predominantly FST IV and V and mild to moderate blemish-prone skin. Early significant improvements from baseline in Skin Clarity were demonstrated with continued, progressive improvement through week 12. Significant improvements in Skin Tone and Pore Size occurred by week 8 with continued improvements through week 12. Visible improvements in the appearance of PIH were observed. Subjects reported high levels of satisfaction with the study products

throughout the study period.

The regimen was well tolerated and no subject discontinued use of study products due to an AE.

References: (1). AAD. <u>https://www.aad.org/media/stats-numbers</u> (2) Callendar VD, et al. J *Clin Aesthet Dermatol*. 2014;7(7):19-31. (3) Callendar VD, et al. *Am J Clin Dermatol*. 2022;23:69-81. (4) Draelos Z, et al. J Cosmet Dermatol. 2016 Mar;15(1):36-42. (5) Robinson DM, et al. J Drugs Dermatol. 2022;21(1):54-59.

